Form Release Summary – January 2026

Contents

Exagamglogene autotemcel (Casgevy®) Pre-Infusion Supplemental Data (2548 R1)

- Exagamglogene autotemcel (Casgevy®) Pre-Infusion Supplemental Data (2548) is a new data collection form to be used for gene therapy recipients. It consists of 19 questions that will collect study relevant baseline and pre-infusion data outside of the scope of CIBMTR standard forms for sickle cell disease and transfusion dependent beta-thalassemia. As a new gene therapy registry form, it will be implemented for corporate client Vertex as part of CIBMTR study CS20-55.
- The form will come due after the following information is completed:
    - On the Pre-Transplant Essential Data (2400), **Exagamglogene autotemcel** is selected as the gene therapy product. On the Disease Classification (2402), **sickle cell disease** or **transfusion dependent beta-thalassemia** is selected as the primary disease. This will enroll the recipient in CS20-55 and place them on the Comprehensive Report Form (CRF) track.
    - Either the Sickle Cell Pre-Infusion (2030) or Thalassemia Pre-Infusion (2058) is completed, as applicable.

Exagamglogene autotemcel (Casgevy®) Post-Infusion Supplemental Data (2549 R1)

- Exagamglogene autotemcel (Casgevy®) Post-Infusion Supplemental Data (2549) is a new data collection form to be used for gene therapy recipients. It consists of 34 questions that will collect study relevant post-infusion data outside of the scope of CIBMTR standard forms for sickle cell disease and transfusion dependent beta-thalassemia. As a new gene therapy registry form, it will be implemented for corporate client Vertex as part of CIBMTR study CS20-55.
- After study enrollment, the form will come due once the Post Infusion Follow-up (2100) is completed along with the Sickle Cell Disease Post-Infusion (2130) or Thalassemia Post-Infusion (2158). It will come due for each standard follow-up timepoint through 15 years (100 days, 6 months, annually for 6 years post-HCT, and biennially thereafter).